Nektar links ‘softening’ response to bempegaldesleukin to CMC issues

A year after Nektar reported decreasing responses to its bempegaldesleukin/Opdivo combination, the biotech thinks it has zeroed in on the reason -- manufacturing. However, the pattern isn’t consistent across different tumor types.

Shares of Nektar Therapeutics (NASDAQ:NKTR) fell $7.77 (26%) to $29.57 in after-hours trading.

Nektar provided the updated analyses of the PIVOT-2 trial results on its 2Q19 earnings

Read the full 580 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE